RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 Insulin Analogs
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 10
SP 14
OP 15
DO 10.1177/155989771210008
UL http://mdc.sagepub.com/content/12/10/14.abstract
AB The basal insulin analog LY2605541 (LY) is a long-acting, PEGylated insulin lispro that is designed with a large hydrodynamic size, which delays insulin absorption and reduces clearance, resulting in prolonged duration of action. LY demonstrates a preferential hepatic effect compared with human insulin in a somatostatin-infused/glucagon-replaced conscious dog model [Moore MC et al. ADA 2012 Abstract 1609P]. This article discusses data that showed that in a continuously glucose-monitored cohort of patients with type 2 diabetes mellitus, those receiving LY had lower intra-day glucose variability and fewer and shorter episodes of hypoglycemia compared with patients receiving glargine.